Klaus Breiner

Klaus Breiner stands as a distinguished Managing Director at Pureos Bioventures, a leading venture capital firm dedicated to advancing innovation within the biopharmaceutical sector. With a profound understanding of drug development and a keen eye for transformative science, Breiner plays a pivotal role in shaping Pureos Bioventures' investment strategy and portfolio growth. His leadership is instrumental in identifying and nurturing companies poised to deliver significant breakthroughs in healthcare.

At Pureos Bioventures, Klaus Breiner is deeply involved in all facets of the investment lifecycle. This includes rigorous due diligence, deal sourcing, and providing strategic guidance to portfolio companies. Pureos Bioventures focuses on early-stage and growth-stage biopharmaceutical companies, particularly those developing novel therapeutic drugs. Breiner's investment philosophy emphasizes supporting ventures with strong scientific foundations, addressing unmet medical needs, and demonstrating clear potential for clinical and commercial success. The firm's portfolio, under his influence, often includes companies innovating in critical therapeutic areas such as oncology, immunology, rare diseases, and neuroscience, reflecting a commitment to diverse and impactful medical advancements.

Breiner's extensive career background provides a robust foundation for his current role. Prior to joining Pureos Bioventures, he held a significant position as a Partner at HBM Partners, another highly respected firm in the life sciences investment landscape. During his tenure there, he gained invaluable experience in venture capital, private equity, and public market investments across various stages of company development. Before his impactful career in venture capital, Klaus Breiner honed his expertise within the pharmaceutical industry itself. He held various strategic roles at global pharmaceutical giants such as Novartis and Roche. His responsibilities often encompassed business development, licensing, and mergers and acquisitions, providing him with a comprehensive understanding of the pharmaceutical value chain from discovery to commercialization. This unique blend of scientific insight, corporate strategy, and investment acumen positions him as a highly effective and respected investor in the biopharmaceutical space.

Klaus Breiner's contributions extend beyond capital allocation; he is a trusted advisor to entrepreneurial teams, helping them navigate the complexities of drug development, clinical trials, and market entry. His commitment to fostering innovation and supporting groundbreaking science underscores his dedication to improving patient outcomes worldwide. Through his strategic vision and deep industry knowledge, Klaus Breiner continues to drive Pureos Bioventures' mission to invest in the next generation of life-saving therapies.